Cargando…

Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis

BACKGROUND: Patients taking low-dose aspirin to prevent cardiovascular disease (CVD) may also benefit from a reduced risk of colorectal cancer (CRC). OBJECTIVE: The aim was to examine the preferences of people eligible for preventive treatment with low-dose aspirin and the trade-offs they are willin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tervonen, Tommi, Vora, Pareen, Seo, Jaein, Krucien, Nicolas, Marsh, Kevin, De Caterina, Raffaele, Wissinger, Ulrike, Soriano Gabarró, Montse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357711/
https://www.ncbi.nlm.nih.gov/pubmed/33829397
http://dx.doi.org/10.1007/s40271-021-00506-2
_version_ 1783737187893772288
author Tervonen, Tommi
Vora, Pareen
Seo, Jaein
Krucien, Nicolas
Marsh, Kevin
De Caterina, Raffaele
Wissinger, Ulrike
Soriano Gabarró, Montse
author_facet Tervonen, Tommi
Vora, Pareen
Seo, Jaein
Krucien, Nicolas
Marsh, Kevin
De Caterina, Raffaele
Wissinger, Ulrike
Soriano Gabarró, Montse
author_sort Tervonen, Tommi
collection PubMed
description BACKGROUND: Patients taking low-dose aspirin to prevent cardiovascular disease (CVD) may also benefit from a reduced risk of colorectal cancer (CRC). OBJECTIVE: The aim was to examine the preferences of people eligible for preventive treatment with low-dose aspirin and the trade-offs they are willing to make between CVD prevention, CRC prevention, and treatment risks. METHODS: A cross-sectional study using a discrete choice experiment (DCE) survey was conducted in Italy in 2019 to elicit preferences for three benefit attributes (prevention of ischemic stroke, myocardial infarction, and CRC) and four risk attributes (intracranial and gastrointestinal bleeding, peptic ulcer, and severe allergic reaction) associated with use of low-dose aspirin. Latent class logit models were used to evaluate variation in treatment preferences. RESULTS: The DCE survey was completed by 1005 participants eligible for use of low-dose aspirin. A four-class model had the best fit for the primary CVD prevention group (n = 491), and a three-class model had the best fit for the secondary CVD prevention group (n = 514). For the primary CVD prevention group, where classes differed on age, education level, type 2 diabetes, exercise, and low-dose aspirin use, the most important attributes were intracranial bleeding (two classes), myocardial infarction (one class), and CRC (one class). For the secondary CVD prevention group, where classes differed on various comorbidities, self-reported health, exercise, and CVD medication use, the most important attributes were intracranial bleeding (two classes), myocardial infarction (one class), and gastrointestinal bleeding (one class). CONCLUSION: Patient preferences for the benefits and risks of low-dose aspirin differ significantly among people eligible for treatment as primary or secondary CVD prevention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40271-021-00506-2.
format Online
Article
Text
id pubmed-8357711
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83577112021-08-30 Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis Tervonen, Tommi Vora, Pareen Seo, Jaein Krucien, Nicolas Marsh, Kevin De Caterina, Raffaele Wissinger, Ulrike Soriano Gabarró, Montse Patient Original Research Article BACKGROUND: Patients taking low-dose aspirin to prevent cardiovascular disease (CVD) may also benefit from a reduced risk of colorectal cancer (CRC). OBJECTIVE: The aim was to examine the preferences of people eligible for preventive treatment with low-dose aspirin and the trade-offs they are willing to make between CVD prevention, CRC prevention, and treatment risks. METHODS: A cross-sectional study using a discrete choice experiment (DCE) survey was conducted in Italy in 2019 to elicit preferences for three benefit attributes (prevention of ischemic stroke, myocardial infarction, and CRC) and four risk attributes (intracranial and gastrointestinal bleeding, peptic ulcer, and severe allergic reaction) associated with use of low-dose aspirin. Latent class logit models were used to evaluate variation in treatment preferences. RESULTS: The DCE survey was completed by 1005 participants eligible for use of low-dose aspirin. A four-class model had the best fit for the primary CVD prevention group (n = 491), and a three-class model had the best fit for the secondary CVD prevention group (n = 514). For the primary CVD prevention group, where classes differed on age, education level, type 2 diabetes, exercise, and low-dose aspirin use, the most important attributes were intracranial bleeding (two classes), myocardial infarction (one class), and CRC (one class). For the secondary CVD prevention group, where classes differed on various comorbidities, self-reported health, exercise, and CVD medication use, the most important attributes were intracranial bleeding (two classes), myocardial infarction (one class), and gastrointestinal bleeding (one class). CONCLUSION: Patient preferences for the benefits and risks of low-dose aspirin differ significantly among people eligible for treatment as primary or secondary CVD prevention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40271-021-00506-2. Springer International Publishing 2021-04-08 2021 /pmc/articles/PMC8357711/ /pubmed/33829397 http://dx.doi.org/10.1007/s40271-021-00506-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Tervonen, Tommi
Vora, Pareen
Seo, Jaein
Krucien, Nicolas
Marsh, Kevin
De Caterina, Raffaele
Wissinger, Ulrike
Soriano Gabarró, Montse
Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
title Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
title_full Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
title_fullStr Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
title_full_unstemmed Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
title_short Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis
title_sort patient preferences of low-dose aspirin for cardiovascular disease and colorectal cancer prevention in italy: a latent class analysis
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357711/
https://www.ncbi.nlm.nih.gov/pubmed/33829397
http://dx.doi.org/10.1007/s40271-021-00506-2
work_keys_str_mv AT tervonentommi patientpreferencesoflowdoseaspirinforcardiovasculardiseaseandcolorectalcancerpreventioninitalyalatentclassanalysis
AT vorapareen patientpreferencesoflowdoseaspirinforcardiovasculardiseaseandcolorectalcancerpreventioninitalyalatentclassanalysis
AT seojaein patientpreferencesoflowdoseaspirinforcardiovasculardiseaseandcolorectalcancerpreventioninitalyalatentclassanalysis
AT kruciennicolas patientpreferencesoflowdoseaspirinforcardiovasculardiseaseandcolorectalcancerpreventioninitalyalatentclassanalysis
AT marshkevin patientpreferencesoflowdoseaspirinforcardiovasculardiseaseandcolorectalcancerpreventioninitalyalatentclassanalysis
AT decaterinaraffaele patientpreferencesoflowdoseaspirinforcardiovasculardiseaseandcolorectalcancerpreventioninitalyalatentclassanalysis
AT wissingerulrike patientpreferencesoflowdoseaspirinforcardiovasculardiseaseandcolorectalcancerpreventioninitalyalatentclassanalysis
AT sorianogabarromontse patientpreferencesoflowdoseaspirinforcardiovasculardiseaseandcolorectalcancerpreventioninitalyalatentclassanalysis